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Abstract
Purpose This study aims to explore the changes in pain
intensity and quality of life (QoL) experienced by patients
with painful diabetic neuropathy (PDN) treated with spinal
cord stimulation (SCS) and conventional medical practice
(CMP).
Methods Patient-reported pain intensity and QoL data
were obtained from participants in an international multi-
centre randomised controlled trial comparing SCS versus
CMP. Data were collected at randomisation and 6 month
follow up by means of a visual analogue scale for pain
intensity, the EuroQoL Visual Analogue Scale (EQ VAS)
and the EuroQol EQ-5D index. Quality-adjusted life years
(QALYs) were calculated for each treatment using the
‘area under the curve’ method. Differences in QALYs were
calculated after adjusting for between-treatment imbal-
ances in baseline QoL.
Results At 6 months, patients allocated to SCS reported
larger reductions in pain intensity and improvements in
QoL measured by the EQ-5D utility score and EQ VAS as
compared to those allocated to CMP. Initial calculations of
QALYs for the SCS and CMP groups suggested no
statistical differences between the groups. Adjusting for
imbalances in baseline EQ-5D scores showed SCS to be
associated with significantly higher QALYs compared to
CMP.
Conclusions SCS resulted in significant improvement in
pain intensity and QoL in patients with PDN, offering
further support for SCS as an effective treatment for
patients suffering from PDN. From a methodological point
of view, different results would have been obtained if
QALY calculations were not adjusted for baseline EQ-5D
scores, highlighting the need to account for imbalances in
baseline QoL.
Keywords EuroQoL-5D  Neuropathic pain  Painful
diabetic neuropathy  Quality of life  Spinal cord
stimulation
Introduction
Diabetes mellitus is a common chronic condition with an
increasing prevalence estimated to reach 4.4 % of the
world population in 2030, the equivalent of 366 million
people [1]. As a result of the condition, approximately one
in every three diabetic patients is expected to develop
painful diabetic neuropathy (PDN) [2, 3]. PDN is defined
as pain arising as a result of abnormalities in the peripheral
somatosensory system in people with diabetes [4], and it is
considered the most disabling and costly complication of
diabetes. Several studies have reported that patients with
neuropathic pain experience lower levels of health-related
quality of life (QoL) when compared to the general pop-
ulation [5, 6]. More specifically, PDN may interfere sub-
stantially with QoL aspects such as general activity, mood,
mobility, self-care, recreational and social activities [7].
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A number of oral pharmacologic treatment options are
available for the management of PDN, including serotonin-
norepinephrine reuptake inhibitors (SNRIs), tricyclic
antidepressants, carbamazepine, venlafaxine, duloxetine,
and amitriptyline. These may be effective for short-term
management of PDN [8]. However, the majority of diabetic
patients report persistent pain over several years even fol-
lowing pharmacologic treatment [9].
Spinal cord stimulation (SCS) is a widely-used inter-
vention for the management of neuropathic pain condi-
tions, and it has been suggested as a promising treatment
option for PDN. Randomised controlled trials (RCTs) have
demonstrated the effectiveness of SCS in the management
of failed back surgery [10] and complex regional pain
syndrome [11]. Recently, the effectiveness of SCS for PDN
was investigated in an RCT comparing SCS against con-
ventional medical practice (CMP) [12]. The results of this
study showed that patients treated with SCS presented
statistically significant improvements in pain relief and
QoL. However, the QoL analysis was merely based on data
captured through the EuroQol visual analogue scale (EQ
VAS). Another recent RCT evaluating SCS for PDN
observed improvements in pain relief but not in QoL [13].
Thus, evidence on the effect of SCS on QoL of patients
with PDN remains inconclusive.
We hypothesise that patients with PDN treated with SCS
obtain larger reductions in pain intensity and improvements
in QoL when compared to those patients with PDN treated
with CMP alone. The aim of this study was to explore the
changes in pain intensity and QoL experienced by patients
with PDN treated with SCS and CMP. To this end, we
analysed patient responses to three instruments (visual
analogue scale for pain intensity (VASPI), EQ VAS, EQ-
5D index) obtained from a multicentre randomised con-
trolled trial.
Methods
Study design and patient recruitment
The design and results of the RCT have been described
previously in detail [12]. In brief, a total of 60 patients
diagnosed with PDN were recruited from seven pain clinics
in the Netherlands, Denmark, Belgium and Germany
between November 2008 and October 2012. Patients were
eligible for inclusion if they were 18 years of age or older,
were diagnosed with refractory diabetic neuropathic pain in
the lower extremities for more than 1 year and had a pain
intensity score of at least 50 on the 100 mm VASPI scale,
which ranges from 0 (no pain) to 100 (worst possible pain)
despite previous treatment with available conventional
treatments. Upon recruitment, patients were stratified for
gender and centre, and were randomised in a 2:1 ratio to
either CMP alone (CMP group, n = 20) or conventional
medical practice supplemented by SCS (SCS group,
n = 40). Patients randomised to the SCS group underwent
a screening trial lasting up to 7 days to assess their
response to SCS, and a pulse generator was only implanted
if the screening trial was successful. 6 months post ran-
domisation, patients in the CMP group could cross over to
SCS therapy if adequate improvement had not been
achieved.
Outcomes and data collection
Information on patients’ age, gender, type and duration of
diabetes, pain intensity and onset of pain was collected
prior to randomisation (baseline). Pain intensity was
assessed using a 100 mm visual analogue scale ranging
from 0 (no pain) to 100 (worst possible pain) [14]. The
VASPI is considered a reliable and valid measure of sub-
jective phenomena including chronic pain [14, 15]. Clini-
cally important changes were determined in accordance
with a consensus statement that established a 10–30 %
decrease as minimal clinically important, C30 % as mod-
erate clinically important and C50 % as a substantial
clinical change [16]. Health-related quality of life was
derived from participants’ responses to the EuroQoL EQ-
5D instrument. This included the EQ VAS and the EQ-5D
(three level) descriptive system. The EQ VAS resembles a
thermometer on which respondents record their self-rated
health where the lower and upper ends are labelled ’worst’
and ’best’ imaginable health state, respectively. The EQ-
5D descriptive system is a questionnaire designed to be
completed by the patient and comprising five dimensions
(mobility, self-care, usual activities, pain/discomfort and
depression/anxiety), where each dimension has three
levels: no problems, some problems and extreme problems.
The respondent is asked to indicate his/her overall health
state by selecting the level that corresponds to his/her
quality of life for each of the five dimensions. Responses to
the EQ-5D descriptive system were converted into single
(utility) indices using a set of weights (tariff) reflecting
population preferences for the particular health state. In
this study, utility scores were obtained by using the Dutch
tariff [17]. QALYs were calculated by the area-under-the-
curve (AUC), involving linear interpolation of utility
indices over the study period [18].
Statistical analysis
Comparisons of scores obtained from self-reported mea-
sures (VASPI, EQ VAS, EQ-5D) between groups were
carried out using independent-samples t tests. Changes in
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these scores between different time points (baseline and
6 month follow up) were assessed using paired-samples
t tests. Changes in levels of EQ-5D dimensions were
evaluated through the Mann–Whitney test for between-
group analyses, and the Wilcoxon signed-rank test for
within-group analyses. Baseline EQ-5D scores are a strong
predictor of total QALY scores, therefore mean differences
in QALYs were calculated after adjusting for imbalances in
baseline scores between groups [19]. Mean differences in
QALYs between the SCS and CMP groups are presented
alongside confidence intervals obtained from 5000 boot-
strap replications (bias corrected and accelerated method).
Sensitivity analyses were carried out using the intention-to-
treat (ITT) principle and missing data imputed using first
observation carried forward. The results of these analyses
were not different from the results presented within this
paper. In addition, we run further analyses to explore the
effect of available covariates, including gender, age,
duration of pain, duration and type of diabetes, baseline
VASPI, EQ VAS and EQ-5D index score. We found that
the only statistically significant variables were group
(treatment group) and baseline EQ-5D index score (data
not shown). Statistical analyses were carried out in STATA
(Release 13.1; College Station, TX: StataCorp LP).
Results
Baseline characteristics of the study sample are reported in
Table 1. Recruited patients had a mean duration of diabetes
of 16 years, with 75 % of them having Type II diabetes.
The mean duration of pain was 7 years. The mean pain
score across all participants was 72 on the VASPI, the
mean EQ-5D utility score obtained from the health status
classification instrument was 0.33 and the mean score
obtained from the EQ VAS was 49. Three patients in the
SCS group did not proceed to implantation of SCS. Two of
these patients did not perceive significant pain relief and in
one patient it was not possible to implant the electrode
lead. One additional patient is the SCS group was with-
drawn despite good response to SCS after deciding to enter
a pharmacological gastroenterology study. In the CMP
group, two patients withdrew consent after 3 months due to
experiencing new diseases unrelated to their PDN condi-
tion. These patients (SCS = 4; CMP = 2) were not
included in the 6-month follow-up analysis.
In the SCS group, minimal clinically important reduc-
tions in pain intensity (10–30 %) were reported by four
(11 %) of the patients, moderate important reductions
(30–50 %) were experienced by three (8 %) while sub-
stantial clinical differences (C50 %) were reported by 24
(67 %) of the patients. Of the patients randomised to CMP,
six (33 %) reported minimal clinically important reduction
in pain intensity and only one (6 %) patient reported
C50 % pain relief.
No statistically significant differences were observed for
the CMP group between baseline and 6-month follow-up
for the VASPI, EQ-5D utility or EQ VAS scores (Table 2).
Statistically significant improvements were observed for all
outcome measures for the patients in the SCS group
between baseline and 6-month follow-up. Patients ran-
domised to SCS experience greater pain relief and greater
improvement in QoL as measured by the EQ-5D utility
scores and EQ VAS than those patients randomised to
CMP. However, the EQ-5D utility scores at baseline were
statistically significantly different between SCS and CMP
groups (Fig. 1).
Comparison of the SCS (M = 0.23, SD = 0.11) and
CMP (M = 0.22, SD = 0.15) groups based on QALYs
calculated as the area under the curve did not show sta-
tistically significant differences between treatments
(p = 0.87; 95 % CI 0.07–0.08). As baseline QoL is a
strong predictor of total QALY scores, we calculated dif-
ferences in QALYs between groups by adjusting for
Table 1 Baseline characteristics
All participants (n = 60) CMP group (n = 20) SCS group (n = 40)
Male, n (%) 38 (63) 13 (65) 25 (63)
Age in years, mean (SD) 59 (11) 61 (12) 58 (11)
Type I diabetes, n (%) 15 (25) 5 (25) 10 (25)
Type II diabetes, n (%) 45 (75) 15 (75) 30 (75)
Duration of diabetes in years, mean (SD) 16 (12) 17 (12) 15 (11)
Duration of pain in years, mean (SD) 7 (5) 7 (6) 7 (6)
Pain VASPI, mean (SD) 72 (15) 67 (18) 73 (16)
EQ-5D, mean (SD) 0.33 (0.29) 0.47 (0.31) 0.27 (0.26)
EQ VAS, mean (SD) 49 (18) 48 (16) 50 (19)
CMP conventional medical practice; SCS spinal cord stimulation; VASPI visual analogue scale for pain intensity
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baseline imbalances in EQ-5D scores (Table 3). The
results showed statistically significant differences in
QALYs between the groups (p\ 0.001; 95 % CI
0.04–0.11). Patients randomised to SCS experienced a
higher QALY gain when compared to the patients
receiving CMP.
On the EQ-5D dimensions, at 6-months the patients ran-
domised to SCS reported significant improvements in four
out of five dimensions: mobility, usual activities, pain/dis-
comfort and anxiety/depression when compared to baseline
(Fig. 2). Statistically significant differences were observed
between groups for the pain/discomfort dimension.
Of the 18 patients that received CMP until 6-months, 14
(78 %) crossed-over to SCS following the 6-month follow-
up. Of the 36 patients that were implanted with an SCS, 34
(94 %) continued to receive SCS therapy after the 6-month
study endpoint.
Discussion
This study analysed data obtained from an international
multicentre RCT to compare the levels of quality of life
reported by patients treated with SCS and CMP. Results
showed that SCS leads to statistical and clinical significant
improvement in pain intensity and quality of life in patients
with PDN as compared to CMP.
Pain intensity findings are consistent with previous non-
randomised studies of SCS in patients with PDN [20–23].
These studies observed that the majority of patients
receiving SCS experienced 50 % pain relief or more after
12 months.
The results of this study are based on a 6-month follow-
up. This was the primary endpoint of the de Vos et al. RCT
[12]. The effects of SCS in pain relief and QoL have been
found to be sustained at 24-month follow-up of RCTs for
other neuropathic pain conditions [24, 25]. It has been
suggested that the effects of SCS for complex regional painT
a
b
le
2
P
ai
n
an
d
E
Q
-5
D
sc
o
re
s
fo
r
th
e
S
C
S
an
d
C
M
P
tr
ea
tm
en
t
g
ro
u
p
s
B
as
el
in
e
6
m
o
n
th
s
W
it
h
in
-g
ro
u
p
d
if
fe
re
n
ce
S
C
S
(n
=
4
0
)
C
M
P
(n
=
2
0
)
S
C
S
-C
M
P
d
if
fe
re
n
ce
S
C
S
(n
=
3
6
)
C
M
P
(n
=
1
8
)
S
C
S
-C
M
P
d
if
fe
re
n
ce
S
C
S
(n
=
3
6
)
C
M
P
(n
=
1
8
)
M
ea
n
(S
D
)
M
ea
n
(S
D
)
M
ea
n
(9
5
%
C
I)
M
ea
n
(S
D
)
M
ea
n
(S
D
)
M
ea
n
(9
5
%
C
I)
M
ea
n
(9
5
%
C
I)
M
ea
n
(9
5
%
C
I)
V
A
S
P
I
7
3
(1
6
)
6
7
(1
8
)
-
6
(-
1
5
to
3
)
2
9
(2
7
)
6
6
(2
2
)
3
7
(2
2
–
5
2
)^
^^
4
6
(3
5
–
)*
*
0
.5
(-
1
0
to
1
1
)
E
Q
-5
D
in
d
ex
0
.2
7
(0
.2
6
)
0
.4
7
(0
.3
1
)
0
.2
0
(0
.0
5
–
0
.3
6
)^
0
.6
5
(0
.2
8
)
0
.4
4
(0
.3
3
)
-
0
.2
1
(-
0
.3
9
to
-
0
.0
4
)^
-
0
.3
9
(-
0
.5
0
to
-
0
.2
9
)*
*
0
.0
0
(-
0
.1
0
to
0
.1
1
)
E
Q
V
A
S
5
0
(1
9
)
4
8
(1
6
)
-
1
(-
1
1
to
8
)
6
1
(2
3
)
4
1
(2
0
)
-
2
0
(-
3
4
to
-
7
)^
^
-
1
2
(-
2
2
to
-
1
)*
7
(-
1
to
1
5
)
C
M
P
co
n
v
en
ti
o
n
al
m
ed
ic
al
p
ra
ct
ic
e;
S
C
S
sp
in
al
co
rd
st
im
u
la
ti
o
n
;
V
A
S
P
I
v
is
u
al
an
al
o
g
u
e
sc
al
e
fo
r
p
ai
n
in
te
n
si
ty
^
p
\
.0
5
;
^^
p
\
.0
1
;
^^
^
p
\
.0
0
1
(b
et
w
ee
n
g
ro
u
p
s)
;
*
p
\
.0
5
;
*
*
p
\
.0
0
1
(w
it
h
in
a
g
ro
u
p
)
Fig. 1 EQ-5D index scores for SCS and CMP at baseline and
6 months follow-up. CMP conventional medical practice; SCS spinal
cord stimulation
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syndrome Type I may diminish after 2 years of treatment
with no differences for pain relief and all other measured
variables between SCS and physical therapy [26]. Over
50 % pain relief after 3 years of SCS therapy was reported
by five out of six patients with PDN in a non-randomised
study [27]. Long-term follow-up of the cohort of this RCT
is required to verify if these results are corroborated in
patients with PDN.
Painful diabetic neuropathy may interfere substantially
with quality of life aspects [7]. Interpretation of the baseline
scores of this trial indicates that the pain experienced by
patients with PDN had a negative impact in their QoL
interfering mainly with their usual activities and mobility.
Four of the five dimensions of the EQ-5D improved signif-
icantly at 6-months following treatment with SCS. Similar
results with SCS have previously been described in a patient
group with failed back surgery syndrome [28]. Significant
improvements in QoL were observed for the patients
receiving SCS based on both the EQ VAS and EQ-5D utility
scores. Recently an additional RCT evaluated SCS com-
pared to best medical treatment in patients with PDN [13].
Statistically significant improvements following SCS were
observed for pain intensity but not for QoL when analysing
both the EQ VAS and the EQ-5D utility scores. The authors
suggested that this may have been due to the large variability
of the data and the limited number of participants. It is
unclear if the analysis of the EQ-5D was adjusted to possible
imbalances in baseline scores. In addition, EQ-5D index
scores reported in this study were calculated based on the UK
tariff although the study was conducted in the Netherlands.
The reasons for choosing to use the UK tariff instead of the
Netherlands one were not presented.
An initial evaluation of the QALYs based on calculation
of the area under the curve suggested that there were no
statistically significant differences between the groups.
However, it has been argued that such results may be
biased due to imbalances in baseline utility scores [19].
Further analysis indicated that the EQ-5D baseline utility
scores were significantly different, with the patients ran-
domised to CMP having greater utility levels. Five outliers
in the EQ-5D baseline utility scores were identified, but
these were in the SCS group and in the upper level.
Therefore, excluding these outliers would only accentuate
the baseline EQ-5D index scores difference between the
groups. Analysis of QALYs while adjusting for the base-
line utility scores resulted in statistically significant dif-
ferences, demonstrating that patients randomised to SCS
obtained greater QALY gains than those receiving CMP.
Not taking into account potential imbalances in baseline
utility scores may result in misleading interpretation of
QALY results with potential implications in the cost-ef-
fectiveness evaluation of treatments.
The subjects of this study were derived from the de Vos
et al. [12] trial which had a number of strengths, including
Table 3 QALYs unadjusted
and adjusted for baseline EQ-
5D score over a period of
6 months per treatment group
SCS CMP Difference 95 % CIs*
QALYs—unadjusted for baseline EQ-5D score 0.226 0.220 0.006 -0.070 0.085
QALYs—adjusted for baseline EQ-5D score 0.258 0.178 0.080^^^ 0.044 0.114
* 95 % non-parametric confidence intervals based on 5000 bootstrap bias corrected replicates
^^^ p\ 0.001
Fig. 2 Comparison of the EQ-5D subcategories in CMP and SCS groups at baseline and 6 month follow-up. CMP conventional medical
practice; SCS spinal cord stimulation
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a low attrition rate and a comprehensive collection of
outcome measures including pain and health-related qual-
ity of life. We believe the current study is the first to
provide a detailed report of the sub-categories of the EQ-
5D in patients with refractory PDN of the lower extremi-
ties. Study limitations included lack of blinding, however
this was not possible with the SCS device used due to the
patients feeling paraesthesia in the area of the pain when
the stimulation is on. We acknowledge that lack of blinding
is a potential source of bias. However, due to the nature of
the intervention and comparator it would not be feasible to
blind patients. Recently developed paraesthesia-free devi-
ces may allow for a double-blind design, with both arms
receiving a device but only one of the arms receiving active
treatment.
Conclusions
In conclusion, the pain experienced by the patients
recruited for this study had a negative impact on their
quality of life. When analysing QALYs based on the area
under the curve, it is important to take into consideration
possible baseline imbalances in EQ-5D utility scores.
Disregarding baseline imbalances could potentially lead to
erroneous and misleading conclusions. Spinal cord stimu-
lation resulted in clinical and statistical improvements in
pain and quality of life of patients with painful diabetic
neuropathy. The results of this study further support spinal
cord stimulation as an effective alternative for those
patients with refractory painful diabetic neuropathy in the
lower extremities.
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